ConductScience.org, home
Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
API referenceFor AI assistants

Trial · NCT02960217

Participant flow24

How many started, completed or left each group, period by period.

1 to 20 of 24

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Maintenance Phase: Treatment Period 1STARTEDDouble-Blind UX007 Followed by Placebo22
Maintenance Phase: Treatment Period 1STARTEDDouble-Blind Placebo Followed by UX00721
Maintenance Phase: Treatment Period 1COMPLETEDDouble-Blind UX007 Followed by Placebo21
Maintenance Phase: Treatment Period 1COMPLETEDDouble-Blind Placebo Followed by UX00721
Maintenance Phase: Treatment Period 1NOT COMPLETEDDouble-Blind UX007 Followed by Placebo1
Maintenance Phase: Treatment Period 1NOT COMPLETEDDouble-Blind Placebo Followed by UX0070
Maintenance Phase: Crossover WashoutSTARTEDDouble-Blind UX007 Followed by Placebo21
Maintenance Phase: Crossover WashoutSTARTEDDouble-Blind Placebo Followed by UX00721
Maintenance Phase: Crossover WashoutCOMPLETEDDouble-Blind UX007 Followed by Placebo21
Maintenance Phase: Crossover WashoutCOMPLETEDDouble-Blind Placebo Followed by UX00721
Maintenance Phase: Crossover WashoutNOT COMPLETEDDouble-Blind UX007 Followed by Placebo0
Maintenance Phase: Crossover WashoutNOT COMPLETEDDouble-Blind Placebo Followed by UX0070
Maintenance Phase: Treatment Period 2STARTEDDouble-Blind UX007 Followed by Placebo21
Maintenance Phase: Treatment Period 2STARTEDDouble-Blind Placebo Followed by UX00721
Maintenance Phase: Treatment Period 2COMPLETEDDouble-Blind UX007 Followed by Placebo20
Maintenance Phase: Treatment Period 2COMPLETEDDouble-Blind Placebo Followed by UX00718
Maintenance Phase: Treatment Period 2NOT COMPLETEDDouble-Blind UX007 Followed by Placebo1
Maintenance Phase: Treatment Period 2NOT COMPLETEDDouble-Blind Placebo Followed by UX0073
Open-Label Extension PhaseSTARTEDDouble-Blind UX007 Followed by Placebo20
Open-Label Extension PhaseSTARTEDDouble-Blind Placebo Followed by UX00713

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02960217/flow

API referenceFor AI assistants